Part 6: Detection and Prevention of Foot Problems in Type 2 Diabetes
Part 6: Detection and Prevention of Foot Problems in Type 2 Diabetes Part 6: Detection and Prevention of Foot Problems in Type 2 Diabetes
McNeely MJ, Boyko EJ, Ahroni JH, Stensel VL, Reiber GE, Smith DG, Pecoraro RF. The independentcontributions of diabetic neuropathy and vasculopathy in foot ulceration. How great are the risks?Diabetes Care 1995;18:216-9.Meade TW, Gardner MJ, Cannon P, Richardson PC. Observer variability in recording peripheralpulses. Br Heart J 1968;30:661-5.Moss SE, Klein R, Klein B. Long-term incidence of lower-extremity amputations in a diabeticpopulation. Arch Fam Med 1996;5:391-8.NADC. ANDIAB. Australian National Diabetes Information Audit and Benchmarking. Final report.National Association of Diabetes Centres; Sydney: 2000.Orchard TJ, Strandness DE Jr. Assessment of peripheral vascular disease in diabetes. Report andrecommendations of an international workshop sponsored by the American Heart Association and theAmerican Diabetes Association 18-20 September 1992, New Orleans, Louisiana. Diabetes Care1993;16:1199-209.Payne CB. Diabetes-related lower-limb amputations in Australia. MJA 2000;173:352-4.Pecoraro RE, Reiber GE. Classification of wounds in diabetic amputees. Wounds 1990;2:65-73. (Can'tfind)Pichert JW, Penha ML. Institutionalization of diabetes care and education programs: A tale of twocities. Diabetes Educ 1993;19:273-7.Pirart J. Degenerative diabetic complications. Is persistent hyperglycemia more dangerous than wideglycemic fluctuations? Nouv Presse Med 1978;7:4031-5.Plummer ES, Albert SG. Foot care assessment in patients with diabetes: A screening algorithm forpatient education and referral. Diabetes Educ 1995;21:47-51.Reiber GE. Epidemiology of the diabetic foot. In: Levin ME, O'Neal LW, Bowker JH. The DiabeticFoot. Mosby Year Book, St Louis. 1993;1-5.Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg 1998;176(Suppl2A):S5-10.Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus.A case-control study. Ann Intern Med 1992;117:97-105.Reiber GE, Smith DG, Boone DA, del Aguila M, Borchers RE, Mathews D, Joseph AW, Burgess EM.Design and pilot testing of the DVA/Seattle Footwear System for diabetic patients with footinsensitivity. J Rehabil Res Dev 1997;34:1-8.Reiber GE, Smith DG, Wallace CM, Vath CA, Sullivan K, Hayes S, Yu O, Martin D, Maciejewski M.Footwear used by individuals with diabetes and a history of foot ulcer. J Rehabil Res Dev2002b;39:615-22.Reiber GE, Vileikyte L, Boyko EJ, del Aguila M, Smith DG, Lavery LA, Boulton AJ. Causal pathwaysfor incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care1999;22:157-62.Shaw JE, Boulton AJ. The pathogenesis of diabetic foot problems: an overview. Diabetes1997;46(Suppl 2):S58-61.Sims DS Jr, Cavanagh PR, Ulbrecht JS. Risk factors in the diabetic foot. Recognition and management.Phys Ther 1988;68:1887-902.112
Sugarman JR, Reiber GE, Baumgardner G, Prela CM, Lowery J. Use of the therapeutic footwearbenefit among diabetic medicare beneficiaries in three states, 1995. Diabetes Care 1998;21:777-81.Tapp RJ, Shaw JE, de Courten MP, Dunstan DW, Welborn TA, Zimmet PZ. Foot complications nType 2 diabetes: an Australian population-based study. Diabet Med 2003;20:105-13.Tkac I, Bril V. Glycemic control is related to the electrophysiologic severity of diabetic peripheralsensorimotor polyneuropathy. Diabetes Care 1998;21:1749-52.Tovey FI. The manufacture of diabetic footwear. Diabet Med 1984;1:69-71.UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared withconventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.Veves A, Murray HJ, Young MJ, Boulton AJ. The risk of foot ulceration in diabetic patients with highfoot pressure: a prospective study. Diabetologia 1992;35:660-3.Young MJ, Veves A, Boulton AJ. The diabetic foot: aetiopathogenesis and management. DiabetesMetab Rev 1993a;9:109-27.Young M, Matthews C. Neuropathy screening: can we achieve our ideals? Diabetic Foot 1998;1:22-5.Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of theprevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population.Diabetologia 1993b;36:150-4.113
- Page 62 and 63: Mazzuca et al (1986) studies 532 pe
- Page 64 and 65: with before the programme, after 1-
- Page 66 and 67: Evidence Table: Section 8AuthorEffe
- Page 68 and 69: Background - Glycaemic Control and
- Page 70 and 71: In a previous Japanese randomised s
- Page 72 and 73: Evidence Table: Section 9AuthorGlyc
- Page 74 and 75: Background - Footwear to Reduce Ulc
- Page 76 and 77: period. In addition people without
- Page 78 and 79: Comparisons of in-shoe foot pressur
- Page 80 and 81: The rate of plantar callus formatio
- Page 82 and 83: Evidence Table: Section 10AuthorFoo
- Page 84 and 85: Background - Foot Clinics and Multi
- Page 86 and 87: A prospective non randomised contro
- Page 88 and 89: Summary - Foot Clinics and Multi-di
- Page 90 and 91: Section 12: Diabetes Foot ProblemsI
- Page 92 and 93: and/or osteomyelitis; III - fore-fo
- Page 94 and 95: Summary - Economic consequences•
- Page 96 and 97: Section 13: Diabetes Foot ProblemsI
- Page 98 and 99: Some ethnic groups are associated w
- Page 100 and 101: Evidence Table: Section 13AuthorSoc
- Page 102 and 103: Calle-Pascual AL, Duran A, Diaz A,
- Page 104 and 105: Jannink MJ, van Dijk H, de Vries J,
- Page 106 and 107: Moss SE, Klein R, Klein BE. The 14-
- Page 108 and 109: Soulier SM, Godsey C, Asay ED, Perr
- Page 110 and 111: Diabetes Foot Problems: General Ref
- Page 114 and 115: Diabetes Foot Problems: Other Refer
- Page 116 and 117: Caputo GM, Cavanagh PR, Ulbrecht JS
- Page 118 and 119: Garbalosa JC, Cavanagh PR, Wu G, Ul
- Page 120 and 121: Lavery LA, Armstrong DG, Wunderlich
- Page 122 and 123: Payne C. Regional variations of dia
- Page 124 and 125: Tovi J, Svanborg E, Nilsson BY, Eng
- Page 126 and 127: Criteria used to determine the suit
- Page 128 and 129: QUESTIONS KEY WORDS NO.ARTICLESIDEN
- Page 130 and 131: QUESTIONS KEY WORDS NO.ARTICLESIDEN
- Page 132 and 133: QUESTIONS KEY WORDS NO.ARTICLESIDEN
- Page 134 and 135: QUESTIONS KEY WORDS NO.ARTICLESIDEN
- Page 136 and 137: QUESTIONS KEY WORDS NO.ARTICLESIDEN
- Page 138 and 139: QUESTIONS KEY WORDS NO.ARTICLESIDEN
Sugarman JR, Reiber GE, Baumgardner G, Prela CM, Lowery J. Use <strong>of</strong> the therapeutic footwearbenefit among diabetic medicare beneficiaries <strong>in</strong> three states, 1995. <strong>Diabetes</strong> Care 1998;21:777-81.Tapp RJ, Shaw JE, de Courten MP, Dunstan DW, Welborn TA, Zimmet PZ. <strong>Foot</strong> complications n<strong>Type</strong> 2 diabetes: an Australian population-based study. Diabet Med 2003;20:105-13.Tkac I, Bril V. Glycemic control is related to the electrophysiologic severity <strong>of</strong> diabetic peripheralsensorimotor polyneuropathy. <strong>Diabetes</strong> Care 1998;21:1749-52.Tovey FI. The manufacture <strong>of</strong> diabetic footwear. Diabet Med 1984;1:69-71.UKPDS 33. Intensive blood-glucose control with sulphonylureas or <strong>in</strong>sul<strong>in</strong> compared withconventional treatment <strong>and</strong> risk <strong>of</strong> complications <strong>in</strong> patients with type 2 diabetes (UKPDS 33). Lancet1998;352:837-53.Veves A, Murray HJ, Young MJ, Boulton AJ. The risk <strong>of</strong> foot ulceration <strong>in</strong> diabetic patients with highfoot pressure: a prospective study. Diabetologia 1992;35:660-3.Young MJ, Veves A, Boulton AJ. The diabetic foot: aetiopathogenesis <strong>and</strong> management. <strong>Diabetes</strong>Metab Rev 1993a;9:109-27.Young M, Matthews C. Neuropathy screen<strong>in</strong>g: can we achieve our ideals? Diabetic <strong>Foot</strong> 1998;1:22-5.Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study <strong>of</strong> theprevalence <strong>of</strong> diabetic peripheral neuropathy <strong>in</strong> the United K<strong>in</strong>gdom hospital cl<strong>in</strong>ic population.Diabetologia 1993b;36:150-4.113